Mainstream

AstraZeneca beats Q4 top-line and bottom-line estimates; initiates FY25 outlook

AstraZeneca beats Q4 top-line and bottom-line estimates; initiates FY25 outlook

Post Contentazn, azncfRead More

You might also be interested in reading Ethereum Price Faces Recovery Hurdle: Examining The Roadblocks Ahead.

February 6, 2025
In Mainstream